Utah to Receive $10 Million from Albertsons Opioid Settlement for Addiction Treatment

Utah will receive more than $10 million as part of a $773.7 million national settlement with Albertsons Companies Inc., marking another significant financial recovery for states seeking to hold corporations accountable for their role in fueling the opioid epidemic.

The Utah Department of Commerce and Attorney General's Office announced the agreement Monday, which requires the grocery store giant to pay approximately $773.7 million nationally, with potential for additional payments if injunctive relief is granted. Albertsons operated in-store pharmacies across Utah during the height of the opioid crisis.

Settlement Structure and Utah's Allocation

The national agreement establishes a maximum $773 million settlement fund, with individual state allocations determined by formulas accounting for population, overdose death rates, and the volume of prescription opioids distributed within each jurisdiction. Utah's $10 million-plus share reflects both its population size and the documented impact of the crisis on Utah communities.

"Utah families are still living with the devastating consequences of the opioid crisis," said Attorney General Derek Brown. "Through litigation involving many states, we reached an agreement in principle with Albertsons in a national settlement over its role in fueling the opioid epidemic. We remain committed to pursuing litigation that protects Utah families and delivers meaningful results."

The settlement funds will flow through Utah's opioid abatement fund, a dedicated mechanism established to ensure settlement dollars reach communities for addiction treatment, recovery services, and prevention efforts rather than disappearing into general state budgets.

How Utah Uses Opioid Settlement Funds

Utah has developed a structured approach to deploying opioid settlement resources, prioritizing evidence-based interventions and community-driven solutions. The state's opioid abatement fund operates under guiding principles that emphasize:

Treatment expansion — Increasing access to medication-assisted treatment for opioid use disorder, including buprenorphine and methadone programs in underserved areas. Utah has historically faced geographic barriers to addiction treatment, with rural communities particularly underserved.

Recovery support services — Funding peer recovery coaches, sober living facilities, and employment assistance programs that help individuals maintain long-term recovery after completing formal treatment.

Prevention and education — School-based prevention programs, community awareness campaigns, and prescriber education initiatives aimed at preventing opioid misuse before it begins.

Harm reduction — Naloxone distribution programs, syringe exchange services, and fentanyl test strip access to reduce overdose deaths among people who use drugs.

"This marks a significant step forward in our commitment to supporting Utah communities impacted by the devastating effects of the opioid crisis," said Margaret Woolley Busse, Utah Department of Commerce executive director. "We stand united in our mission to heal our communities and prevent further tragedies from occurring."

The Albertsons Settlement in National Context

The Albertsons agreement represents the latest in a series of massive legal settlements with companies across the pharmaceutical supply chain. National settlements to date have exceeded $50 billion, creating unprecedented resources for addressing an epidemic that has claimed more than 700,000 American lives.

Major settlement categories include:

• Pharmaceutical manufacturers — Purdue Pharma ($6 billion), Johnson & Johnson ($5 billion), Teva ($4.2 billion), and others for aggressive marketing and downplaying addiction risks

• Distributors — McKesson, Cardinal Health, and AmerisourceBergen ($21 billion combined) for failing to monitor and report suspicious opioid orders

• Retail pharmacies — CVS ($5 billion), Walgreens ($5.7 billion), Walmart ($3.1 billion), and now Albertsons ($773 million) for dispensing opioids without adequate safeguards

Each settlement includes requirements that companies change their business practices, with pharmacy settlements typically mandating enhanced prescription monitoring, pharmacist training, and limits on opioid dispensing.

Utah's Previous Settlement Recoveries

The Albertsons payment adds to substantial resources Utah has already secured through opioid litigation. In June 2023, the state received $209 million from drug makers Teva and Allergan, plus pharmacies CVS and Walgreens, as part of separate national settlements.

Combined with earlier recoveries from Purdue Pharma and the major distributors, Utah has secured hundreds of millions in opioid settlement funds. The cumulative resources enable comprehensive approaches that individual settlements could not fund alone.

Challenges in Settlement Fund Deployment

While settlement dollars provide crucial resources, states face significant challenges in deploying them effectively:

Geographic distribution — Utah's rural character creates logistical challenges for delivering services across vast distances. Remote communities often lack treatment infrastructure, requiring mobile services or telehealth solutions.

Workforce shortages — Addiction medicine specialists, psychiatrists, and certified peer recovery coaches remain scarce, particularly in rural Utah. Settlement funds must compete for limited personnel.

Sustainability concerns — Settlement payments typically span 15-18 years, creating planning challenges. Programs initiated with settlement funds need transition plans to sustainable funding or face closure when payments end.

Accountability and measurement — Ensuring funds achieve measurable outcomes rather than simply expanding existing programs requires robust evaluation systems that many states are still developing.

Looking Forward

The Albertsons settlement arrives as Utah and other states refine their approaches to opioid settlement deployment. Early spending focused heavily on naloxone distribution and treatment expansion, while more recent allocations increasingly emphasize recovery support, employment assistance, and addressing social determinants of health.

For Utah communities still grappling with overdose deaths, treatment waiting lists, and the long-term consequences of the epidemic, the $10 million represents both accountability and hope. The settlement acknowledges corporate responsibility for community devastation while providing resources to address ongoing needs.

The challenge now lies in spending these dollars wisely — in programs that save lives, support recovery, and prevent future generations from experiencing the losses that have defined the past two decades.

---

If you or someone you know is struggling with opioid addiction, help is available. Visit SAMHSA's treatment locator or call 1-800-662-4357. For immediate overdose response, naloxone is available without prescription at most Utah pharmacies. Explore our guides to opioid addiction treatment and medication-assisted recovery.